Novartis to pay Monte Rosa $150m upfront for MGD drug candidates
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.
Drugs
Health
Pharma
Drugs
Health
Pharma
Novartis’s drug to treat rare kidney disease gets USFDA approval
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.
Drugs
Health
Pharma
Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets
HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..
Drugs
Health
Pharma
Novartis to pay $100m upfront to Voyager for gene therapies
HQ Team January 3, 2023: Voyager Therapeutics, Inc., will receive an upfront payment of $100 million from Switzerland-based Novartis AG to develop gene.
Drugs
Health
Pharma
USFDA green lights Sandoz’s biosimilar Tyruko to treat multiple sclerosis
HQ Team August 25, 2023: The US drug regulator gave its nod for Sandoz Inc., an arm of Sweden-based Novartis and which is.
Drugs
Medical
Pharma
Novartis sells eye business to Bausch+Lomb for $2.5 billion
HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.
Drugs
Health
Pharma
Novartis to acquire Chinook Therapeutics in a $3.5 billion deal
HQ Team June 13, 2023: Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental.
Drugs
Pharma
Novartis AG stops breast cancer trial as it achieves early success
Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage.